Imlifidase denied as duplicate or overlapping therapy by Aetna?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Aetna typically requires
Aetna's specific coverage criteria for imlifidase are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Aetna angle on Imlifidase
## Why Aetna Denies Imlifidase as Duplicate Therapy
Imlifidase (Idefirix) is an enzyme used in a very specific clinical context — principally to cleave immunoglobulin G antibodies in highly sensitized kidney transplant candidates, enabling transplantation that would otherwise be blocked by high levels of donor-specific antibodies. Because it is used immediately before transplantation as a preparatory agent rather than as an ongoing maintenance therapy, a "duplicate therapy" denial from Aetna generally means Aetna's review system has identified another agent or procedure in the patient's record that it classifies as serving the same clinical function.
In reality, imlifidase has no direct therapeutic equivalent — no other approved agent performs rapid IgG cleavage in this setting. The duplicate-therapy denial therefore frequently rests on a coding or categorization error, or on Aetna applying a standard utilization-management rule that was not designed for this drug's unique mechanism.
## Your Federal Appeal Rights
- Internal appeal: ACA §2719 and ERISA §503 guarantee a full-and-fair internal review. Submit a written appeal within the timeframe stated on your denial letter, which your plan documents may extend.
- External review: If the internal appeal is denied, independent external review is available within approximately four months of the final internal adverse determination. An IRO not affiliated with Aetna reviews the case.
- Expedited review: Given the transplant context, clinical urgency is often present. Request expedited review explicitly; decisions are typically rendered within 72 hours or fewer when urgency is documented.
## What to Gather Before You File
1. Identification of the alleged duplicate: The denial letter must identify what therapy Aetna considers duplicative. Obtain this and share it with the treating transplant team immediately. 2. Transplant team clinical letter: The transplant nephrologist or immunologist should explain, in writing, the specific clinical function of imlifidase (rapid IgG cleavage to enable transplantation), why it is not duplicated by any other agent the patient is receiving or has received, and why it is medically necessary for this patient's transplant to proceed. 3. FDA-approved prescribing information for imlifidase: Confirms the specific, narrow indication and the mechanism of action, which distinguishes it from all other agents. 4. Patient sensitization and compatibility workup: Documentation of the patient's panel-reactive antibody levels and HLA typing establishing the clinical need for desensitization at the time of transplant. 5. Transplant program clinical records: Records confirming the transplant candidacy evaluation, listing committee, and planned procedure date.
## Criteria-Mapping Structure
| Aetna's Duplicate-Therapy Claim | Your Response | Supporting Document | |---|---|---| | Identifies [alleged duplicate agent] | That agent does not perform IgG cleavage | Transplant team letter + FDA label | | Same clinical function as imlifidase | Mechanistically distinct — no overlap | FDA prescribing information | | Medical necessity of imlifidase | Required for this transplant to proceed | Sensitization workup + team letter |
This type of denial often resolves at the internal-appeal stage once the transplant team's clinical letter is reviewed by a physician with relevant specialty expertise.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →